Serabelisib Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: FTH-001, MLN1117

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

Faeth Therapeutics2

Indications

Cancer2
HR+/HER2- Breast Cancer1
Endometrial Cancer1
Breast Cancer1

La Jolla, California1 trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

UC San Diego Moores Cancer Center

Phase 2

Los Angeles, California1 trial

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

START Los Angeles

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.